IRIS
LA MONICA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.575
NA - Nord America 2.512
AS - Asia 964
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
SA - Sud America 1
Totale 6.058
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.485
CN - Cina 770
IE - Irlanda 581
IT - Italia 564
SE - Svezia 524
FI - Finlandia 383
DE - Germania 190
UA - Ucraina 148
TR - Turchia 84
IN - India 42
GB - Regno Unito 40
AT - Austria 38
BE - Belgio 38
CA - Canada 27
SG - Singapore 26
FR - Francia 25
NL - Olanda 17
HK - Hong Kong 11
IR - Iran 10
JP - Giappone 9
VN - Vietnam 8
CZ - Repubblica Ceca 7
HU - Ungheria 4
RO - Romania 4
CH - Svizzera 3
LU - Lussemburgo 3
EU - Europa 2
NZ - Nuova Zelanda 2
PL - Polonia 2
AL - Albania 1
AU - Australia 1
ES - Italia 1
HR - Croazia 1
IL - Israele 1
KR - Corea 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
SI - Slovenia 1
ZA - Sudafrica 1
Totale 6.058
Salva come PNG Salva come JPEG
Città #
Dublin 579
Chandler 515
Ann Arbor 314
Parma 191
Jacksonville 185
Beijing 168
Dearborn 167
Ashburn 151
Nanjing 116
Princeton 89
Izmir 82
Shanghai 71
Boardman 61
New York 59
Bremen 57
Wilmington 57
San Mateo 55
Nanchang 50
Kunming 48
Shenyang 46
Vienna 38
Helsinki 34
Hefei 31
Des Moines 29
Hebei 29
Los Angeles 29
Jinan 28
Tianjin 27
Seattle 22
Brussels 21
Grafing 21
Woodbridge 21
Pune 20
Toronto 20
Milan 19
Norwalk 19
Redmond 19
Changsha 18
Guangzhou 17
Jiaxing 17
Modena 17
Rome 17
Fremont 15
Leawood 13
Wayne 12
Bologna 11
Amsterdam 10
Hong Kong 10
Redwood City 10
Reggio Emilia 10
Augusta 9
Houston 9
Dong Ket 8
Monmouth Junction 8
Ningbo 8
Rio Saliceto 8
Ardabil 7
Binche 7
Lanzhou 7
Neviano degli Arduini 7
Fuzhou 6
Haikou 6
Leuven 6
Mestre 6
Taiyuan 6
Auburn Hills 5
Castello Molina di Fiemme 5
London 5
Paris 5
Zhengzhou 5
Busseto 4
Chengdu 4
Fairfield 4
Ferrara 4
Mons 4
Mumbai 4
Pavia 4
Pesaro 4
Albano Laziale 3
Albignasego 3
Borås 3
Cuneo 3
Düsseldorf 3
Edinburgh 3
Florence 3
Gainesville 3
Hangzhou 3
Kagoya 3
Luxembourg 3
Piacenza 3
Prata Di Pordenone 3
Rockville 3
Rubiera 3
Savignano sul Rubicone 3
Shaoxing 3
Singapore 3
Sissa 3
Taizhou 3
Xian 3
Candiac 2
Totale 3.895
Salva come PNG Salva come JPEG
Nome #
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 120
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 115
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 111
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 99
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 99
Characterization of gefitinib uptake in NSCLC cell lines 97
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 97
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 94
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 92
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 89
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 87
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 87
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 85
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 84
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 83
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 83
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 82
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 82
Physico-chemical characterization and biological evaluation of two fibroin materials 81
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 81
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 80
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 80
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 80
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 79
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 78
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 78
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 78
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 77
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 76
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 76
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 75
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 72
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 71
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 69
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 69
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 69
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 69
Multiple myeloma patient with unusual extramedullary involvement 68
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 68
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 68
Osteopontin is produced by human multiple myeloma cells 67
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 67
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 66
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 66
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 65
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 64
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 64
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 63
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 63
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 61
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 61
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 59
Multiple myeloma patient with unusual extramedullary involvement 59
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 58
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 58
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 57
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 56
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 56
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 55
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 54
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 54
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 52
Optimizing EGFR inhibitor treatment in non small cell lung cancer 52
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 51
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 50
Synergistic activity of letrozole and sorafenib on breast cancer cells 50
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 50
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 50
Evaluation of gefitinib maintenance in an EGFR-mutant NSCLC cell line with acquired resistance 49
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 49
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 49
Overcoming resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer cell lines 49
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 49
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 49
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 48
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 48
Successful regrowth of retinal neurons when cultured interfaced to carbon nanotube platforms 48
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 48
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 47
RANKL is critically involved in the physiopathology of multiple myeloma 46
RANKL is critically involved in the physiopathology of multiple myeloma 45
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 45
Erlotinib potentiates Cetuximab-dependent cell citotoxicity in EGFR wild-type NSCLC cell lines 44
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry 43
Targeting FGFR1 pathway in squamous cell lung cancer 39
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 39
New therapeutic strategies for malignant pleural mesothelioma 38
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 36
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells 36
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 34
Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells 32
null 31
Interaction between occupational radon exposure and tobacco smoke: a systematic review 28
Human myeloma cells stimulate the receptor activator of NF-KB Ligad (RANKL) in T cells: Role of interleukin-7 28
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 27
Generation and characterization of a new preclinical mouse model of egfr-driven lung cancer with met-induced osimertinib resistance 27
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 23
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 22
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 21
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 20
Totale 6.193
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.096
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.096
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019116 0 0 0 0 0 0 0 0 0 0 108 8
2019/20201.173 170 216 48 26 71 131 154 47 102 101 53 54
2020/2021613 15 54 29 21 70 16 54 40 101 26 135 52
2021/2022574 36 15 52 41 20 25 88 50 31 22 40 154
2022/20232.246 211 239 153 152 198 248 45 143 700 17 101 39
2023/2024731 35 75 35 47 82 186 86 85 44 55 1 0
Totale 6.227